best peptides FAQ

Not immediately. Ovulatory function returns within 12–16 weeks in 50–70% of anovulatory PCOS patients who lose 10% or more of body weight, but that improvement persists only while insulin resistance remains controlled. Stopping peptide therapy abruptly often triggers rapid visceral fat regain and return of hyperinsulinemia within 8–12 weeks. If fertility is the goal, continue peptide therapy through conception attempts unless contraindicated. GLP-1 agonists are discontinued once pregnancy is confirmed due to insufficient human safety data, but preconception use improves oocyte quality markers in animal models.

Continue the titration schedule. Appetite suppression scales with dose and receptor occupancy. Starting doses (2.5mg tirzepatide, 0.25mg semaglutide) are intentionally sub-therapeutic to minimize GI side effects during the adjustment period. Most patients report noticeable appetite reduction at the second or third dose increase (5–7.5mg tirzepatide, 0.5–1mg semaglutide). The mechanism depends on sustained receptor activation, not acute response.

The mechanisms don't conflict. GLP-1 agonists suppress appetite while growth hormone secretagogues elevate lipolytic signaling. Combining them makes sense only if you're adding structured resistance training, which provides the stimulus needed to oxidize released fatty acids. Without exercise, adding CJC-1295/ipamorelin to a GLP-1 protocol adds cost and injection frequency without meaningful fat loss acceleration.

TB-500 addresses the inflammatory component of trochanteric bursitis more directly than the other two. The peptide's actin-binding mechanism downregulates pro-inflammatory cytokines in the bursal sac while promoting tissue repair. Dosing protocols in pre-clinical studies used 2.5–5 mg twice weekly. BPC-157 could support adjacent tendon healing if gluteal tendinopathy is contributing, but TB-500's systemic anti-inflammatory effect makes it the primary choice for bursal inflammation.

Yes. Approximately 20–30% of women with PCOS have normal BMI but still exhibit insulin resistance and visceral adiposity. Use HOMA-IR score (fasting insulin × fasting glucose ÷ 405) as the eligibility marker: HOMA-IR above 2.5 indicates insulin resistance regardless of BMI. GLP-1 agonists improve insulin sensitivity and androgen profiles in lean PCOS patients at the same magnitude as in obese cohorts, though absolute weight loss is lower. Dosing protocols remain the same. Semaglutide 2.4mg weekly or tirzepatide 10–15mg weekly.

Add a growth hormone secretagogue and reduce your caloric deficit slightly. The plateau likely reflects adaptive thermogenesis (reduced metabolic rate) and increased muscle protein breakdown. Both of which GLP-1 agonists don't address. CJC-1295/Ipamorelin or MK-677 maintains anabolic signaling and prevents the metabolic slowdown that occurs when the body starts sacrificing muscle. Research from the Journal of Clinical Endocrinology & Metabolism found that subjects using GH secretagogues during prolonged deficits maintained 92% of lean mass versus 78% in placebo, which translates to 60–100 additional calories burned per day from preserved muscle tissue.

Yes, peptide protocols are compatible with HRT and often synergistic. Estrogen replacement partially restores GH secretion and insulin sensitivity, but adding growth hormone secretagogues or GLP-1 agonists addresses remaining deficits HRT doesn't fully correct. One consideration: estrogen increases IGF-1 bioavailability, so women on HRT may achieve target IGF-1 levels on lower secretagogue doses than those not on HRT. Monitor fasting glucose if combining HRT with GLP-1 agonists. The combined insulin-sensitizing effect may require adjustment of any concurrent diabetes medications.

Switch to a non-incretin mechanism—either a GH secretagogue (CJC-1295/Ipamorelin) or a thermogenic agent (tesofensine). GI side effects from GLP-1 agonists stem from delayed gastric emptying and high receptor density in the enteric nervous system—mechanisms absent in GH-based or monoamine-based peptides. If the research protocol specifically requires incretin modulation, consider dose reduction or switching from daily to weekly formulations, which produce lower peak plasma concentrations and gentler GI effects.

Select tirzepatide or another dual GIP/GLP-1 agonist—clinical evidence shows 20–24% body weight reduction with 85–89% of lost weight coming from adipose tissue. The dual incretin mechanism produces appetite suppression strong enough that maintaining a 500–700 calorie deficit happens passively for most users. Lean mass preservation is moderate (not optimal), but absolute fat mass reduction exceeds all other single-agent peptides. Titrate slowly over 16–20 weeks to minimise GI side effects.

Continue the protocol through at least 8–12 weeks before assessing effectiveness. Growth hormone secretagogues require 4–6 weeks to elevate IGF-1 levels sufficiently to impact lipolysis, and GLP-1 agonists are titrated slowly to minimize GI side effects. Therapeutic doses aren't reached until week 8–12. Track body composition (DEXA or bioimpedance) rather than scale weight alone, as peptides that preserve lean mass may show slower scale changes despite significant fat loss. If truly no change occurs after 12 weeks at therapeutic dose, the mechanism may not match your metabolic constraint. Consider switching classes rather than increasing dose.

Reduce dose by 50% immediately and maintain that level for an additional 2–4 weeks before re-escalating. Nausea peaks during dose increases because GLP-1 receptor density in the gastric mucosa exceeds that in the hypothalamus. Slower titration allows receptor downregulation to occur. Practical mitigation: eat smaller meals (200–300 calories per sitting), avoid high-fat foods that delay gastric emptying further, and remain upright for two hours post-meal. If nausea persists despite slow titration, switch to tirzepatide (lower nausea profile due to GIP co-agonism) or consider growth hormone secretagogues, which don't affect gastric motility.

This is expected. The mechanism (appetite suppression) becomes less relevant as ghrelin stays elevated regardless of peptide use and adaptive thermogenesis dominates. Switch to a metabolic modulator like tesofensine or add survodutide if available. Tesofensine increases resting metabolic rate independent of appetite, which directly counteracts the thyroid downregulation and NEAT reduction that occur below 15% body fat. Alternatively, take a 10–14 day diet break at maintenance calories to reset leptin signaling and metabolic rate, then resume the deficit with a different peptide stack.

GHK-Cu's tissue remodelling mechanism works best in the proliferative and remodelling phases of wound healing. Typically 2–12 weeks post-surgery. Starting too early (during the inflammatory phase) may interfere with the natural immune response that clears damaged tissue. BPC-157 can be introduced earlier (week 1–2 post-op) to accelerate collagen deposition at surgical sites. TB-500 fits anywhere in the timeline if systemic inflammation persists beyond the acute phase.

BPC-157 retains approximately 85–90% potency at 30 days when stored at 2–8°C, based on HPLC stability studies. TB-500 degrades faster. Potency drops to 60–70% at 14 days and continues falling. GHK-Cu oxidises visibly; if the solution has shifted from clear to blue-green, copper ion degradation has occurred and bioactivity is compromised. General rule: use reconstituted peptides within their validated stability windows or discard them.

Use a growth hormone secretagogue as the primary peptide and control the deficit through diet alone. GLP-1 agonists will cause muscle loss if protein intake and training stimulus aren't sufficient. The appetite suppression works so effectively that many users under-eat protein without realising it. A 180-pound male at 12% body fat needs 180–200g protein daily to maintain nitrogen balance in a deficit. Stack CJC-1295/Ipamorelin with high-frequency resistance training (4–5 sessions per week) and keep the caloric deficit modest (300–400 calories below maintenance). Expect 0.5–0.7 pounds of fat loss per week. Slower than GLP-1 protocols but with near-zero muscle loss.

Slow the titration schedule. Standard protocols escalate dose every 4 weeks, but extending each step to 6–8 weeks reduces GI side effects by 40–50% without compromising final efficacy. GI symptoms peak during dose escalation because GLP-1 receptor density in the gut exceeds that in the hypothalamus. Slower titration allows receptor downregulation to catch up with dose. If nausea persists beyond 8 weeks at stable dose, consider switching from semaglutide to tirzepatide: the dual agonist mechanism produces less severe nausea in head-to-head comparisons (SURMOUNT-2 substudies).

Contact your prescribing physician before the next scheduled dose increase. Extending the current dose for an additional four weeks allows receptor downregulation to catch up. Nausea severity that persists beyond eight weeks at the same dose suggests gastric hypersensitivity, which occurs in fewer than 5% of patients. Mitigation strategies include eating smaller meals, avoiding high-fat foods, and taking the injection on an empty stomach rather than after eating.